Dehal S S, Kupfer D
Worcester Foundation for Biomedical Research and Department of Pharmacology and Molecular Toxicology, University of Massachusetts Medical Center, Worcester, Massachusetts 01655, USA.
Drug Metab Dispos. 1999 Jun;27(6):681-8.
Earlier study suggested that 3,4-dihydroxytamoxifen (tam catechol), a tamoxifen metabolite, is proximate to the reactive intermediate that binds covalently to proteins and possibly to DNA (). The current study demonstrates that rat and human hepatic cytochrome P-450s (CYPs) catalyze tam catechol formation from tamoxifen (tam), 3-hydroxy-tam (Droloxifene), and 4-hydroxy-tam (4-OH-tam). Higher levels of catechol were formed from 4-OH-tam and 3-hydroxy-tam than from tam. Evidence that human hepatic CYP3A4 and 2D6 catalyze the formation of tam catechol from 4-OH-tam and supportive data that the catechol is proximate to the reactive intermediate, was obtained: 1) There was a good correlation (r = 0.82; p </=.0004) between steroidal 6beta-hydroxylase (CYP3A activity) and ortho hydroxylation of 4-OH-tam in human liver microsomes; 2) monospecific antibodies against CYP3A4 strongly inhibited catechol formation from 4-OH-tam and its covalent binding to proteins in human liver microsomes; 3) low levels of ketoconazole inhibited catechol tam accumulation and covalent binding of 4-OH-tam to human liver proteins; 4) among human P-450s expressed in insect cells (supersomes), only CYP3A4 and 2D6 noticeably catalyzed catechol formation, and cytochrome b5 markedly stimulated the CYP3A4 catalysis; and 5) human livers with high CYP3A and low or high CYP2D6 activity exhibited high catechol formation and those with low 3A and 2D6 activities formed only little catechol. These findings demonstrate that CYP3A4 and to a lesser extent 2D6 catalyze tam catechol formation and support the participation of tam catechol in covalent binding to proteins.
早期研究表明,他莫昔芬的代谢产物3,4-二羟基他莫昔芬(他莫昔芬儿茶酚)接近与蛋白质并可能与DNA共价结合的反应性中间体()。当前研究表明,大鼠和人肝脏细胞色素P-450(CYPs)催化他莫昔芬(他莫昔芬)、3-羟基他莫昔芬(屈洛昔芬)和4-羟基他莫昔芬(4-OH-他莫昔芬)生成他莫昔芬儿茶酚。与他莫昔芬相比,4-OH-他莫昔芬和3-羟基他莫昔芬生成的儿茶酚水平更高。已获得以下证据,即人肝脏CYP3A4和2D6催化4-OH-他莫昔芬生成他莫昔芬儿茶酚,以及支持该儿茶酚接近反应性中间体的数据:1)人肝微粒体中甾体6β-羟化酶(CYP3A活性)与4-OH-他莫昔芬的邻位羟化之间存在良好的相关性(r = 0.82;p≤.0004);2)针对CYP3A4的单特异性抗体强烈抑制人肝微粒体中4-OH-他莫昔芬生成儿茶酚及其与蛋白质的共价结合;3)低水平的酮康唑抑制儿茶酚他莫昔芬的积累以及4-OH-他莫昔芬与人肝蛋白质的共价结合;4)在昆虫细胞(超微粒体)中表达的人P-450中,只有CYP3A4和2D6显著催化儿茶酚生成,并且细胞色素b5显著刺激CYP3A4的催化作用;5)具有高CYP3A活性和低或高CYP2D6活性的人肝脏表现出高儿茶酚生成,而具有低3A和2D6活性的肝脏仅生成少量儿茶酚。这些发现表明CYP3A4以及程度较轻的2D6催化他莫昔芬儿茶酚的生成,并支持他莫昔芬儿茶酚参与与蛋白质的共价结合。